Feedback
Settings

Settings

Goto Application

283,010 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,301
1.20250223328TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS
US - 10.07.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No 19091382 Applicant The Trustees of Columbia University in the City of New York Inventor Lloyd A. GREENE

Truncated dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the truncated dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasing viability of neoplastic cells and treating cancer in a subject are also described.

2.20250223329BIFUNCTIONAL FUSION PROTEIN COMPOSED OF IL-15 AND ANTIBODY AGAINST T CELL CO-STIMULATORY MOLECULE
US - 10.07.2025
Int.Class C07K 14/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins
 Appl.No 18408650 Applicant Institute of Biophysics, Chinese Academy of Sciences Inventor Yangxin Fu

The present disclosure relates to a bifunctional fusion protein composed of IL-15 and an antibody against a T cell co-stimulatory molecule. The T cell co-stimulatory molecule is 4-1BB, ICOS or OX40, preferably 4-1BB; the fusion protein comprises: (1) an antibody against a T cell co-stimulatory molecule; (2) a conjugate of IL-15 and IL-15R Sushi domain linked by a second linker; and (3) a matrix metalloproteinase-cleavable first linker for linking the Fc region of the heavy chain of the antibody against the T cell co-stimulatory molecule to the conjugate of IL-15 and IL-15R Sushi domain.

3.20250223348PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER
US - 10.07.2025
Int.Class C07K 16/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
 Appl.No 19094472 Applicant CARDIFF ONCOLOGY, INC. Inventor Maya Ridinger

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

4.20250222127COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TRANSPLANT-ASSOCIATED INJURY
US - 10.07.2025
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No 18884976 Applicant MUSC Foundation For Research Development Inventor Stephen Tomlinson

Described herein are compositions and methods for treating or preventing an injury associated with transplant. Specifically, the disclosure provides a composition for treating or preventing an injury associated with transplantation, comprising (a) a targeted inhibitor molecule wherein the targeted inhibitor molecule comprises a targeting portion and an inhibitor portion, wherein the molecule inhibits complement pathways, and (b) a sub-therapeutic dose of an immunosuppressant agent. Further provided are methods of treating or preventing an injury associated with transplantation with activated complement by using the compositions.

5.WO/2025/145965PYRROLE SULFONAMIDE ANTACID CRYSTAL AND PREPARATION METHOD THEREFOR AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION
WO - 10.07.2025
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No PCT/CN2024/142891 Applicant ZHEJIANG MEDICINE CO., LTD XINCHANG PHARMACEUTICAL FACTORY Inventor LI, Nanxing
The present invention relates to a pyrrole sulfonamide antacid crystal and a preparation method therefor and the use thereof, and a pharmaceutical composition. Specifically, disclosed in the present invention is a pyrrole sulfonamide antacid crystal of a compound of formula (I), and the chemical structural formula of the crystal is as represented by formula (I), wherein n=0.1 to 2.0. The crystal form has good stability, fluidity and humidity resistance; and the preparation method for the crystal form involves a simple process, is easy to control and is suitable for large-scale production.
6.WO/2025/147555REC-4881 (TAK-733) FOR USE IN TREATING OR PREVENTING COLORECTAL CANCER AND RELATED DISEASES
WO - 10.07.2025
Int.Class A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
 Appl.No PCT/US2025/010152 Applicant RECURSION PHARMACEUTICALS, INC. Inventor TOUTOUNCHIAN, Jordan
Methods are provided for treating or preventing colorectal cancer, related diseases, or symptoms of any of the foregoing, e.g., familial adenomatous polyposis (FAP), in subjects of 55 years or older. The methods include administering 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4, 7-dione or a pharmaceutically acceptable salt thereof.
7.WO/2025/146445PHARMACEUTICAL COMPOSITIONS OF OBICETRAPIB AND EZETIMIBE
WO - 10.07.2025
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
 Appl.No PCT/EP2025/050018 Applicant NEWAMSTERDAM PHARMA B.V. Inventor CUI, Sheng
Provided herein are pharmaceutical compositions comprising obicetrapib, or a pharmaceutically acceptable salt, solvate or co-crystal thereof, including, for example, obicetrapib calcium, obicetrapib calcium which, as used herein, is obicetrapib hemicalcium, and which may, in many embodiments, be amorphous obicetrapib hemicalcium; ezetimibe; a surfactant and optionally one or more additional pharmaceutically acceptable excipients. Also provided are pharmaceutical dosage forms including the same processes for making such pharmaceutical compositions, and methods for using such pharmaceutical compositions in the treatment of subjects including in treatments requiring reduction in LDL cholesterol and/or an increase in HDL cholesterol and other ailments.
8.20250222031Treatment of Disc Degeneration using B Regulatory Cells
US - 10.07.2025
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
 Appl.No 19015315 Applicant CREATIVE MEDICAL TECHNOLOGIES, INC. Inventor Thomas Ichim

Compositions of matter, interventions and protocols for treatment of degenerative disc disease through administration of B regulatory cells and/or stimulation of B regulatory cell generation. B regulatory cells can be administered intradiscally in order to support regenerative processes of endogenous nucleus pulposus cells or administered regenerative cells. Peri-spinal administration of B regulatory cells can alter the microenvironment to support activity of therapeutic cells capable of increasing extracellular matrix quality and quantity. B regulatory cells can be expanded in vitro from progenitor cells including induced pluripotent stem cells, or may be utilized from adult progenitor sources such as peripheral blood, cord blood, and bone marrow.

9.20250222118Beta-Lactam-Cannabinoid Conjugate Molecules
US - 10.07.2025
Int.Class A61K 47/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
55the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
 Appl.No 19086538 Applicant Diverse Biotech, Inc. Inventor Paul Hershberger

This disclosure provides multifunctional conjugate molecules in which at least one β-lactam antibiotic is covalently attached to a cannabinoid by means of a linker. The disclosed conjugate molecules are designed to deliver therapeutic benefits as intact molecules, with release of the cannabinoid upon binding of the β-lactam antibiotic to its target conveying further therapeutic benefits, and can be used to treat bacterial infections and other disorders.

10.20250223311MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF
US - 10.07.2025
Int.Class C07H 15/256
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20Carbocyclic rings
24Condensed ring systems having three or more rings
256Polyterpene radicals
 Appl.No 19011159 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor David Y. GIN

Truncated saponin analogues are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and methods of using the truncated saponin analogues.

# -